Source Feed: Global News - Canada
Author: Globalnews Digital
Publication Date: July 16, 2026 - 09:35
Stay informed
Unpublished Opinions
Add Alzheimer’s drug lecanemab to Canada’s public drug plans, agency says
July 16, 2026
Lecanemab is an antibody that targets the buildup of amyloid plaque in the brain, which is believed to be an underlying cause of the disease.
Unpublished Newswire
July 22, 2026 - 22:00 | Simon Houpt | The Globe and Mail
July 22, 2026 - 21:44 | Willow Fiddler | The Globe and Mail
The measures, threatened by U.S. President Donald Trump, would impose a 50 per cent tariff on hundreds of Canadian product categories valued at roughly $20 billion.
July 22, 2026 - 21:37 | Alessia Simona Maratta | Global News - Canada
Comments
Be the first to comment